Health Expenses and Outcomes of the DASH Diet in Egyptian Patients With Hypertension

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

364 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-01-01

Study Completion Date

2024-06-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

DASH diet can reduce hypertension and decrease health expenses

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Dash Diet and Acupuncture on Hypertention in Postmenopausal Women

NCT06015919

Postmenopausal Disorder

COMPLETED NA

Modifying Dietary Behavior in Adolescents With Elevated Blood Pressure

NCT00585832

Hypertension Pre-Hypertension

COMPLETED NA

Lifestyle Changes in Patients With Type 2 Diabetes Mellitus and Hypertension

NCT01461330

Blood Pressure

TERMINATED NA

Dietary Approaches to Stop Hypertension (DASH)

NCT00000544

Cardiovascular Diseases Heart Diseases Hypertension +1 more

COMPLETED PHASE3

Effects of the DASH vs. the Mediterranean Diet Combined With Salt Restriction on Blood Pressure Levels in Adults

NCT05669404

Hypertension

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertension is a prevalent cardiovascular risk factor associated with adverse outcomes and obesity. Egypt's prevalence is 26.3%, exceeding rates in the U.S. and sub-Saharan Africa. Lifestyle interventions like the DASH diet effectively manage hypertension, offering a cost-effective alternative to pharmacological treatments. This study aims to assess the effects of the DASH diet on blood pressure, BMI, waist circumference, and fasting blood glucose, as well as its cost-effectiveness compared to pharmacological treatments. This open-label prospective controlled clinical trial was conducted in Esna Health Administration, Luxor Governorate. The FMREC of Beni-Suef University approved the study, which included 364 hypertensive patients aged 30-60. Exclusions were patients with severe comorbidities or those who declined participation. Measurements included height, weight, BMI, blood pressure, and laboratory tests. The intervention group received a DASH diet education program. Outcomes measured were blood pressure, BMI, waist circumference, weight, and fasting blood glucose at baseline and post-intervention. Our study demonstrates the significant benefits of the DASH diet in managing blood pressure, weight, and fasting blood glucose levels in the Egyptian population. The DASH diet substantially reduced systolic and diastolic blood pressure, with a notable decrease in the number of antihypertensive medications needed. Additionally, participants on the DASH diet experienced significant weight loss and reduced BMI and waist circumference compared to the control group. The economic implications of the DASH diet are also promising, with a notable decrease in the total cost of therapy due to reduced medication costs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension,Essential

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

an Open-label parallel design prospective controlled clinical trial

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

intervention group

Participants will taken a medical history review, anthropometric assessments, and waist circumference measurements. Tests included hemoglobin levels, kidney and liver function tests, fasting blood glucose, and lipid profiles. Baseline antihypertensive medications will be recorded in an Excel sheet and taken DASH diet .

Group Type ACTIVE_COMPARATOR

DASH diet

Intervention Type OTHER

The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons

control group

Participants will taken a medical history review, anthropometric assessments, and waist circumference measurements. Tests included hemoglobin levels, kidney and liver function tests, fasting blood glucose, and lipid profiles. Baseline antihypertensive medications will be recorded in an Excel sheet and without taken DASH diet .

Group Type PLACEBO_COMPARATOR

DASH diet

Intervention Type OTHER

The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DASH diet

The Dietary Approaches to Stop Hypertension (DASH) diets rich in fruits and vegetables and reduced in saturated fat can lower the risk for high blood pressure and assist with blood pressure control in hypertensive persons

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients diagnosed with primary hypertension (all stages) in the family medicine units of Esna Health Administration, located in Luxor Governorate.
* Individuals between the ages of 30 and 60, of both male and female genders.

Exclusion Criteria

* • Patients with cancer and either hepatic failure or renal impairment.

* Patients diagnosed with diabetes, metabolic illness, or terminal organ failure.
* A patient with severe or malignant hypertension.
* Individuals who decline to partake in our research.

Minimum Eligible Age

30 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes